Fujirebio Highlights Its Innovative IVD Testing Solutions for Today and Tomorrow at MEDICA 2021

Fujirebio Diagnostics AB (Gothenburg, Sweden) highlighted its innovative IVD testing solutions at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany.

Fujirebio’s IVD product lines span from specialized manual testing to fully automated routine clinical laboratory testing solutions and include both novel and routine biomarkers. The company covers a variety of disease states such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone metabolism. At MEDICA 2021, Fujirebio presented LUMIPULSE G1200, a robust mid-sized fully automated immunoassay instrument that uses a unique mono test cartridge concept with a true throughput of 120 tests per hour. Also on display was the LUMIPULSE G600II, the latest member of the LUMIPULSE G series, the chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio. LUMIPULSE G600II is a compact and robust benchtop analyzer featuring a constant throughput of 60 tests per hour. The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories.

Among its kits for fully automated testing, Fujirebio highlighted Lumipulse® G B•R•A•H•M•S PCT, the most sensitive fully automated Procalcitonin (PCT) test. Immunoreaction cartridges for in vitro diagnostic (IVD) use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma. The CE marked assay utilizes proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes. Fujirebio showcased its portfolio of COVID-19 diagnostic tests, including the Lumipulse G SARS-CoV-2 S-IgG which is an assay system, including a set of immunoassay reagents, for the quantitative measurement of IgG-type antibodies SARS-CoV-2 spike protein (SARS-CoV-2 S-IgG) in specimens based on CLEIA technology by a specific two-step immunoassay method on the LUMIPULSE G System and with results that are available in up to 30 minutes.

In addition, Fujirebio highlighted the Lumipulse G SARS-CoV-2 Ag for in vitro diagnostic (IVD) use with the Lumipulse G system for the detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. The CE marked assay utilizes proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes.

Related Links:
Fujirebio Europe 

Visit expo >

Gold Member

TORCH Panel Rapid Test

Rapid TORCH Panel Test

Gold Member

Pharmacogenetics Panel

VeriDose Core Panel v2.0

New

Zonulin ELISA

IDK Zonulin (Serum) ELISA

New

Carcinoembryonic Antigen Test

CEA Test